Yahoo boards note from James:Investing in biostocks for many years. CRLs are not the end-all. It is a process. TXMD for example, received a CRL in 2017 from the FDA and the requested a Type A meeting and asked for a "conditional approval" with intent to conduct a follow-up study. FDA agreed and TXMD has 3 approved products. (Sidenote: the CEO diluted 4 times since 2017 so that is why the stock sank.) The point is that you can find countless other examples of CRLs that were minor delays. MESO is going to win this one. Aside from that, 3 other catalysts for larger markets coming up in this quarter. Don't be fooled by the buzzards trying to get you to sell your shares.
MSB - Panic > Averaged down > Entry point., page-21
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.33 |
Change
0.045(3.50%) |
Mkt cap ! $1.518B | |||
| Open | High | Low | Value | Volume |
| $1.30 | $1.35 | $1.30 | $2.885M | 2.183M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 7070 | 1 |
View Market Depth
| Last trade - 16.10pm 06/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |